Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2014
Price : $35 *
At a glance
- Drugs Trevogrumab (Primary)
- Indications Muscular atrophy
- Focus Pharmacodynamics
- Sponsors Regeneron Pharmaceuticals
- 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 10 Jun 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 10 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.